Geode Capital Management LLC Grows Stock Position in Aadi Bioscience, Inc. (NASDAQ:AADI)

Geode Capital Management LLC increased its position in Aadi Bioscience, Inc. (NASDAQ:AADIFree Report) by 4.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 217,294 shares of the company’s stock after buying an additional 8,546 shares during the quarter. Geode Capital Management LLC’s holdings in Aadi Bioscience were worth $686,000 at the end of the most recent reporting period.

Separately, BML Capital Management LLC lifted its holdings in shares of Aadi Bioscience by 5.0% in the 4th quarter. BML Capital Management LLC now owns 2,100,000 shares of the company’s stock valued at $6,626,000 after acquiring an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 52.08% of the company’s stock.

Aadi Bioscience Trading Up 0.7 %

Shares of AADI opened at $1.48 on Friday. Aadi Bioscience, Inc. has a twelve month low of $1.21 and a twelve month high of $3.81. The company has a market cap of $36.55 million, a P/E ratio of -0.65 and a beta of 0.68. The company’s fifty day simple moving average is $1.86 and its 200-day simple moving average is $2.34.

Aadi Bioscience (NASDAQ:AADIGet Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.37). Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. The firm had revenue of $7.24 million during the quarter, compared to the consensus estimate of $7.45 million. Analysts predict that Aadi Bioscience, Inc. will post -2.04 earnings per share for the current fiscal year.

Aadi Bioscience Company Profile

(Free Report)

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

Further Reading

Want to see what other hedge funds are holding AADI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aadi Bioscience, Inc. (NASDAQ:AADIFree Report).

Institutional Ownership by Quarter for Aadi Bioscience (NASDAQ:AADI)

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.